- Home
- CNTX vs NOW Comparison
CNTX vs NOW Comparison
Compare CNTX & NOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- NOW
- Stock Information
- Founded
- CNTX 2015
- NOW 2004
- Country
- CNTX United States
- NOW United States
- Employees
- CNTX 9
- NOW N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- NOW Computer Software: Prepackaged Software
- Sector
- CNTX Health Care
- NOW Technology
- Exchange
- CNTX Nasdaq
- NOW Nasdaq
- Market Cap
- CNTX 76.5M
- NOW N/A
- IPO Year
- CNTX 2021
- NOW 2012
- Fundamental
- Price
- CNTX $1.02
- NOW $1,091.25
- Analyst Decision
- CNTX Strong Buy
- NOW Buy
- Analyst Count
- CNTX 4
- NOW 28
- Target Price
- CNTX $7.38
- NOW $1,024.59
- AVG Volume (30 Days)
- CNTX 234.3K
- NOW 1.3M
- Earning Date
- CNTX 11-06-2024
- NOW 01-22-2025
- Dividend Yield
- CNTX N/A
- NOW N/A
- EPS Growth
- CNTX N/A
- NOW N/A
- EPS
- CNTX N/A
- NOW 6.43
- Revenue
- CNTX N/A
- NOW $10,464,000,000.00
- Revenue This Year
- CNTX N/A
- NOW $23.53
- Revenue Next Year
- CNTX N/A
- NOW $20.51
- P/E Ratio
- CNTX N/A
- NOW $169.81
- Revenue Growth
- CNTX N/A
- NOW 23.48
- 52 Week Low
- CNTX $0.89
- NOW $637.99
- 52 Week High
- CNTX $2.75
- NOW $1,157.90
- Technical
- Relative Strength Index (RSI)
- CNTX 17.93
- NOW 54.09
- Support Level
- CNTX $1.17
- NOW $1,056.99
- Resistance Level
- CNTX $1.61
- NOW $1,157.90
- Average True Range (ATR)
- CNTX 0.11
- NOW 28.89
- MACD
- CNTX -0.03
- NOW -8.87
- Stochastic Oscillator
- CNTX 9.15
- NOW 44.91
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.